NCT05450965 - Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 19, 2022

Primary Completion Date

August 31, 2027

Study Completion Date

November 30, 2027

Conditions

Small-cell Lung CancerSmall Cell Lung Carcinoma

Interventions

DRUG

Onvansertib

Onvansertib at a dose of 15 mg/m2 orally on Days 1-14 of a 21-day cycle. Treatment will continue until disease progression or intolerable toxicity.

Trial Locations (2)

ACTIVE_NOT_RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

RECRUITING

University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore